Physician profile
Dennis S Mann
NPI 1962540062
$1,311.43
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $200 · 2021: $629 · 2022: $25.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $270.98 | 2019-2022 | |
| Abbvie INC. | $253.59 | 2021 | |
| Pfizer INC. | $235.35 | 2019-2021 | |
| Allergan, INC. | $150.30 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $123.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.73 | 2019 | |
| Collegium Pharmaceutical, INC. | $67.32 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $54.55 | 2020-2022 | |
| Kaleo, INC. | $24.65 | 2019 | |
| Glaxosmithkline, LLC. | $23.78 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $20.84 | 2021 | |
| Indivior INC. | $18.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.